Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling

Cancer Cell

Volumn 28, Issue 6, 2015, Pages 758-772

  Sun, Shaogang ^a   Chen, Song ^a   Liu, Fei ^b   Wu, Haige ^a   McHugh, Jonathan ^c   Bergin, Ingrid L ^b   Gupta, Anita ^a   Adams, Denise ^a   Guan, Jun Lin ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Angiosarcoma; Lymphangiosarcoma; Mouse models; MTORC1 signaling; Vascular anomalies; Vascular tumor; VEGF

Indexed keywords

AXITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; HIF1A PROTEIN, HUMAN; HIF1A PROTEIN, MOUSE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; MYC PROTEIN; MYC PROTEIN, HUMAN; MYC PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; DEVELOPMENT; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; LYMPHANGIOSARCOMA; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; VASCULAR TUMOR; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; GENOTYPE; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PHENOTYPE; RETINA NEOVASCULARIZATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; AUTOCRINE COMMUNICATION; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME ACTIVATION; GENOTYPE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHANGIOSARCOMA; MICE, KNOCKOUT; MICE, NUDE; MULTIPROTEIN COMPLEXES; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINAL NEOVASCULARIZATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSFECTION; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84959088866     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.10.004     Document Type: Article

References (44)

1. Agulnik M., Yarber J.L., Okuno S.H., von Mehren M., Jovanovic B.D., Brockstein B.E., Evens A.M., Benjamin R.S. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann. Oncol. 2013, 24:257-263.
2. Azurdia R.M., Guerin D.M., Verbov J.L. Chronic lymphoedema and angiosarcoma. Clin. Exp. Dermatol. 1999, 24:270-272.
3. Baudino T.A., McKay C., Pendeville-Samain H., Nilsson J.A., Maclean K.H., White E.L., Davis A.C., Ihle J.N., Cleveland J.L. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002, 16:2530-2543.
4. Boscolo E., Bischoff J. Vasculogenesis in infantile hemangioma. Angiogenesis 2009, 12:197-207.
5. Cohen S.M., Storer R.D., Criswell K.A., Doerrer N.G., Dellarco V.L., Pegg D.G., Wojcinski Z.W., Malarkey D.E., Jacobs A.C., Klaunig J.E., et al. Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance. Toxicol. Sci. 2009, 111:4-18.
6. Crino P.B., Nathanson K.L., Henske E.P. The tuberous sclerosis complex. N. Engl. J. Med. 2006, 355:1345-1356.
7. Du W., Gerald D., Perruzzi C.A., Rodriguez-Waitkus P., Enayati L., Krishnan B., Edmonds J., Hochman M.L., Lev D.C., Phung T.L. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin. Lab. Invest. 2013, 93:1115-1127.
8. El-Hashemite N., Walker V., Zhang H., Kwiatkowski D.J. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 2003, 63:5173-5177.
9. Enjolras O., Mulliken J.B. Vascular tumors and vascular malformations (new issues). Adv. Dermatol. 1997, 13:375-423.
10. Enjolras O., Wassef M., Chapot R. Color Atlas of Vascular Tumors and Vascular Malformations 2007, Cambridge University Press, Cambridge, England.
11. Foster K.G., Fingar D.C. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J. Biol. Chem. 2010, 285:14071-14077.
12. Göthert J.R., Gustin S.E., van Eekelen J.A., Schmidt U., Hall M.A., Jane S.M., Green A.R., Göttgens B., Izon D.J., Begley C.G. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 2004, 104:1769-1777.
13. Greenberger S., Bischoff J. Infantile hemangioma-mechanism(s) of drug action on a vascular tumor. Cold Spring Harb. Perspect. Med. 2011, 1:a006460.
14. Hammill A.M., Wentzel M., Gupta A., Nelson S., Lucky A., Elluru R., Dasgupta R., Azizkhan R.G., Adams D.M. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr. Blood Cancer 2011, 57:1018-1024.
15. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18:1926-1945.
16. Hobson B., Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br. J. Cancer 1984, 49:405-413.
17. Hu-Lowe D.D., Zou H.Y., Grazzini M.L., Hallin M.E., Wickman G.R., Amundson K., Chen J.H., Rewolinski D.A., Yamazaki S., Wu E.Y., et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res. 2008, 14:7272-7283.
18. Huang J., Dibble C.C., Matsuzaki M., Manning B.D. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell. Biol. 2008, 28:4104-4115.
19. Jeng M.R., Fuh B., Blatt J., Gupta A., Merrow A.C., Hammill A., Adams D. Malignant transformation of infantile hemangioma to angiosarcoma: response to chemotherapy with bevacizumab. Pediatr. Blood Cancer 2014, 61:2115-2117.
20. Karkkainen M.J., Ferrell R.E., Lawrence E.C., Kimak M.A., Levinson K.L., McTigue M.A., Alitalo K., Finegold D.N. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet. 2000, 25:153-159.
21. Kwiatkowski D.J. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol. Ther. 2003, 2:471-476.
22. Kwiatkowski D.J., Zhang H., Bandura J.L., Heiberger K.M., Glogauer M., el-Hashemite N., Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 2002, 11:525-534.
23. Lackner H., Karastaneva A., Schwinger W., Benesch M., Sovinz P., Seidel M., Sperl D., Lanz S., Haxhija E., Reiterer F., et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur. J. Pediatr. 2015, Published online June 4, 2015. 10.1007/s00431-015-2572-y.
24. Leech J.D., Lammers S.H., Goldman S., Auricchio N., Bronson R.T., Kwiatkowski D.J., Sahin M. A vascular model of Tsc1 deficiency accelerates renal tumor formation with accompanying hemangiosarcomas. Mol. Cancer Res. 2015, 13:548-555.
25. Lohela M., Bry M., Tammela T., Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 2009, 21:154-165.
26. Maharaj A.S., Saint-Geniez M., Maldonado A.E., D'Amore P.A. Vascular endothelial growth factor localization in the adult. Am. J. Pathol. 2006, 168:639-648.
27. Mankey C.C., McHugh J.B., Thomas D.G., Lucas D.R. Can lymphangiosarcoma be resurrected? A clinicopathological and immunohistochemical study of lymphatic differentiation in 49 angiosarcomas. Histopathology 2010, 56:364-371.
28. Medici D., Olsen B.R. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PLoS ONE 2012, 7:e42913.
29. Miettinen M., Wang Z.F. Prox1 transcription factor as a marker for vascular tumors-evaluation of 314 vascular endothelial and 1086 nonvascular tumors. Am. J. Surg. Pathol. 2012, 36:351-359.
30. Montaner S., Sodhi A., Pece S., Mesri E.A., Gutkind J.S. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res. 2001, 61:2641-2648.
31. Montaner S., Sodhi A., Molinolo A., Bugge T.H., Sawai E.T., He Y., Li Y., Ray P.E., Gutkind J.S. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003, 3:23-36.
32. Onda H., Lueck A., Marks P.W., Warren H.B., Kwiatkowski D.J. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 1999, 104:687-695.
33. Ono S., Tanioka M., Fujisawa A., Tanizaki H., Miyachi Y., Matsumura Y. Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib. Arch. Dermatol. 2012, 148:683-685.
34. Pawlik T.M., Paulino A.F., McGinn C.J., Baker L.H., Cohen D.S., Morris J.S., Rees R., Sondak V.K. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003, 98:1716-1726.
35. Phung T.L., Ziv K., Dabydeen D., Eyiah-Mensah G., Riveros M., Perruzzi C., Sun J., Monahan-Earley R.A., Shiojima I., Nagy J.A., et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006, 10:159-170.
36. Pitulescu M.E., Schmidt I., Benedito R., Adams R.H. Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice. Nat. Protoc. 2010, 5:1518-1534.
37. Quarmyne M.O., Gupta A., Adams D.M. Lymphangiosarcoma of the thorax and thoracic vertebrae in a 16-year-old girl. J. Clin. Oncol. 2012, 30:e294-e298.
38. Riou S., Morelon E., Guibaud L., Chotel F., Dijoud F., Marec-Berard P. Efficacy of rapamycin for refractory hemangioendotheliomas in Maffucci's syndrome. J. Clin. Oncol. 2012, 30:e213-e215.
39. Rossi S., Fletcher C.D. Angiosarcoma arising in hemangioma/vascular malformation: report of four cases and review of the literature. Am. J. Surg. Pathol. 2002, 26:1319-1329.
40. Shirazi F., Cohen C., Fried L., Arbiser J.L. Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat. Res. Biol. 2007, 5:233-236.
41. Sodhi A., Montaner S., Patel V., Gómez-Román J.J., Li Y., Sausville E.A., Sawai E.T., Gutkind J.S. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc. Natl. Acad. Sci. USA 2004, 101:4821-4826.
42. Sodhi A., Chaisuparat R., Hu J., Ramsdell A.K., Manning B.D., Sausville E.A., Sawai E.T., Molinolo A., Gutkind J.S., Montaner S. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006, 10:133-143.
43. Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., Ranieri E., Gesualdo L., Schena F.P., Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 2005, 352:1317-1323.
44. Tang N., Wang L., Esko J., Giordano F.J., Huang Y., Gerber H.P., Ferrara N., Johnson R.S. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004, 6:485-495.